Drugs / APD209
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00895726 | Mar 2009 → Nov 2011 | — | Acacia Pharma Ltd | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01977443 Comparator | Nov 2013 → Sep 2016 | viral conjunctivitis | Adenovir Pharma AB | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APD209 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00895726 ↗ |
| Route | Oral | “Oral tablets twice per day for 56 days” NCT00895726 ↗ |